Publications by authors named "E Montes-Servin"
Ovarian cancer (OC) is gynecologic cancer with the highest mortality rate. It is estimated that 13-17% of ovarian cancers are due to heritable mutations in and . The (-Del ex9-12) Mexican founder mutation is responsible for 28-35% of the cases with ovarian cancer.
View Article and Find Full Text PDFEndometrial cancer is the second gynecological cancer with the highest global incidence. Among many associated risk factors, metabolic syndrome is an important and preventable one. It comprises a group of conditions that often occur together: central adiposity, hyperglycemia, arterial hypertension, and atherogenic dyslipidemia.
View Article and Find Full Text PDFArticle Synopsis
- The study focused on the effectiveness of liquid biopsies for identifying EGFR mutations in non-small-cell lung cancer (NSCLC) patients treated with EGFR-TKIs.
- About 59.5% of the 84 patients showed detectable plasma EGFR mutations, with higher rates in those who experienced disease progression.
- Patients without plasma EGFR mutations had significantly better progression-free survival (PFS) and overall survival (OS) compared to those with mutations, suggesting the importance of monitoring these mutations in treatment outcomes.
Purpose: The impact of disease activity or treatments on health-related quality of life (HRQL) is crucial in Oncology, but adequate instruments for this assessment are scarce. Our aim is to validate the Mexican-Spanish version of the QLQ-EN24 questionnaire to evaluate HRQL in women with endometrial cancer (EC).
Methods: This is a prospective study of Mexican women with EC, attending a single cancer centre, who responded the QLQ-C30 and QLQ-EN24 instruments; usual psychometric analysis were performed as well as the association of HRQL scales and relevant clinical data.
Background: Health-related quality of life (HRQL) is an important outcome measure in Oncology.
Aim Of The Study: To validate the Mexican-Spanish version of the QLQ-OV28 questionnaire to assess HRQL in women with ovarian cancer (OC).
Methods: The QLQ-C30 and QLQ-OV28 instruments were applied to women with OC attending a cancer center in Mexico.